PARP Inhibitors in Prostate and Urothelial Cancers

PARP Inhibitors in Prostate and Urothelial Cancers

Poly(ADP-ribose) polymerase (PARP) inhibitors targeting DNA repair gene mutations have shown significant clinical benefit in patients with ovarian and breast cancers. In metastatic prostate cancers, the prevalence of DNA repair gene mutations is up to 20%, and early phase studies have shown clinical...

Full description

Bibliographic Details
Main Authors: Rohan Garje, Raju Kumar Vaddepally, Yousef Zakharia
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Oncology
Subjects:
prosate cancer
urothelial cancer (UC)
PARP inhibitor
precision oncology
DNA damage repair genes
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00114/full
Description
Summary:Poly(ADP-ribose) polymerase (PARP) inhibitors targeting DNA repair gene mutations have shown significant clinical benefit in patients with ovarian and breast cancers. In metastatic prostate cancers, the prevalence of DNA repair gene mutations is up to 20%, and early phase studies have shown clinical activity of PARP inhibitors. Numerous clinical trials with either PARP monotherapy or in combination with other therapeutic agents are ongoing in prostate cancer. In this comprehensive review, we provide the rationale, efficacy, and safety data of PARP inhibitors in prostate as well as urothelial cancers.
ISSN:2234-943X

Similar Items